KYTX
Kyverna Therapeutics, Inc.10.24
-0.58-5.36%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
448.47MP/E (TTM)
-Basic EPS (TTM)
-3.73Dividend Yield
0%Recent Filings
8-K
Appoints Miller, Emany to board
Kyverna Therapeutics appointed biotech veterans Andrew Miller, Ph.D., and Sravan Emany to its board on February 24, 2026, effective immediately, with Miller joining Science and Technology and Audit Committees, and Emany chairing Audit while sitting on Nominating and Governance. This follows Daniel Spiegelman's resignation the prior day, with no disagreements noted. New directors get $40,000 annual cash plus $262,000 options and $87,500 RSUs each. Board bolsters clinical and financial expertise for growth.
8-K
CTO transition with manufacturing expert
Kyverna Therapeutics sees CTO Karen Walker retire effective February 9, 2026—not due to disagreements—succeeded seamlessly by Mayo Pujols, who brings 30+ years scaling CAR T manufacturing. Smooth transition aids miv-cel BLA submission in stiff person syndrome. Company boosts inducement plan share pool to 5M shares; Pujols gets 300,000-share option. Leadership continuity bolsters commercialization push.
8-K
Shaw named Executive Chairperson
Kyverna appointed Board member Christi Shaw as Executive Chairperson effective January 12, 2026, with $400,000 salary and equity grants including options for 185,000 shares, RSUs for 30,000 shares, and $200,000 PRSUs. This bolsters CAR T commercialization expertise ahead of SPS BLA filing in 1H 2026. Cash stands at ~$279M, runway into 2028. Shaw adds proven leadership.
8-K
Prices $100M offering
Kyverna Therapeutics priced a $100 million public offering of 13,333,333 common shares at $7.50 each on December 17, 2025, expecting to close December 18. Underwriters led by J.P. Morgan gained a 30-day option for 1,999,999 more shares. Net proceeds fund R&D and operations. Lock-ups bind insiders until January 31, 2026.
8-K
Positive miv-cel topline in SPS
Kyverna announced positive topline data from KYSA-8, its registrational Phase 2 trial of miv-cel in stiff person syndrome, on December 15, 2025. Miv-cel hit statistical significance on the primary Timed 25-Foot Walk endpoint (P=0.0002) and all secondary endpoints, with 81% achieving clinically meaningful mobility gains and all patients off immunotherapies. Data backs BLA submission in 1H 2026. Safety proved manageable.
ARTV
Artiva Biotherapeutics, Inc.
4.55-1.75
CABA
Cabaletta Bio, Inc.
2.39+0.00
CRBU
Caribou Biosciences, Inc.
1.69-0.02
FBRX
Forte Biosciences, Inc.
23.27+1.31
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
NKTX
Nkarta, Inc.
1.82-0.02
NTLA
Intellia Therapeutics, Inc.
9.12-0.02
RNAC
Cartesian Therapeutics, Inc.
8.29-0.68
VERA
Vera Therapeutics, Inc.
48.30-0.91
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75